Compare Stocks: CYRX, FTRE, ALMR, and BLFS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMR Alamar Biosciences	$29.58 -5.9%	$30.86	$18.84 ▼ $39.61	$2.05B	N/A	403,692 shs	450,934 shs
BLFS BioLife Solutions	$38.61	$37.11	$17.86 ▼ $39.76	$1.89B	1.82	1.18 million shs	N/A
CYRX CryoPort	$17.82 -3.8%	$16.63	$7.61 ▼ $18.73	$902.58M	1.96	604,228 shs	453,600 shs
FTRE Fortrea	$23.73 -1.4%	$19.45	$8.55 ▼ $24.84	$2.26B	1.93	1.53 million shs	1.14 million shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMR Alamar Biosciences	+11.68%	+23.97%	-10.27%	+21.48%	+3,144,999,900.00%
BLFS BioLife Solutions	0.00%	0.00%	+3.85%	+25.48%	+39.49%
CYRX CryoPort	+6.25%	+11.36%	+5.16%	+15.60%	+82.56%
FTRE Fortrea	+5.62%	+12.75%	+20.18%	+23.38%	+131.57%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMR Alamar Biosciences	$29.58 -5.9%	$30.86	$18.84 ▼ $39.61	$2.05B	N/A	403,692 shs	450,934 shs
BLFS BioLife Solutions	$38.61	$37.11	$17.86 ▼ $39.76	$1.89B	1.82	1.18 million shs	N/A
CYRX CryoPort	$17.82 -3.8%	$16.63	$7.61 ▼ $18.73	$902.58M	1.96	604,228 shs	453,600 shs
FTRE Fortrea	$23.73 -1.4%	$19.45	$8.55 ▼ $24.84	$2.26B	1.93	1.53 million shs	1.14 million shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMR Alamar Biosciences	+11.68%	+23.97%	-10.27%	+21.48%	+3,144,999,900.00%
BLFS BioLife Solutions	0.00%	0.00%	+3.85%	+25.48%	+39.49%
CYRX CryoPort	+6.25%	+11.36%	+5.16%	+15.60%	+82.56%
FTRE Fortrea	+5.62%	+12.75%	+20.18%	+23.38%	+131.57%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALMR Alamar Biosciences	2.57	Moderate Buy	$31.80	7.51% Upside
BLFS BioLife Solutions	2.09	Hold	$31.38	-18.74% Downside
CYRX CryoPort	2.80	Moderate Buy	$19.33	8.49% Upside
FTRE Fortrea	2.42	Hold	$22.80	-3.92% Downside

Current Analyst Ratings Breakdown

Latest CYRX, FTRE, ALMR, and BLFS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/20/2026	FTRE Fortrea	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$22.00 ➝ $24.00
10/15/2026	FTRE Fortrea	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	FTRE Fortrea	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Buy	$20.00 ➝ $25.00
10/13/2026	CYRX CryoPort	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$26.00
10/13/2026	CYRX CryoPort	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy
10/13/2026	CYRX CryoPort	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$25.00 ➝ $26.00
10/12/2026	FTRE Fortrea	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/8/2026	ALMR Alamar Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D+) ➝ Hold (C-)
10/8/2026	CYRX CryoPort	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D) ➝ Hold (C-)
10/6/2026	FTRE Fortrea	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Equal Weight ➝ Overweight	$22.00 ➝ $23.00
10/1/2026	CYRX CryoPort	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$16.00 ➝ $19.00

(Data available from 10/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALMR Alamar Biosciences	$74.21M	27.66	N/A	N/A	N/A	∞
BLFS BioLife Solutions	$106.69M	17.71	$0.23 per share	168.62	$7.72 per share	5.00
CYRX CryoPort	$176.18M	5.12	N/A	N/A	$9.19 per share	1.94
FTRE Fortrea	$2.72B	0.83	$10.32 per share	2.30	$6.10 per share	3.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALMR Alamar Biosciences	-$29.82M	-$1.96	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BLFS BioLife Solutions	-$4.59M	$1.16	33.28	241.31	N/A	53.29%	2.70%	2.49%	11/5/2026 (Estimated)
CYRX CryoPort	$78.30M	-$0.90	N/A	N/A	N/A	-20.05%	-7.20%	-4.30%	11/3/2026 (Estimated)
FTRE Fortrea	-$986.20M	-$0.91	N/A	22.82	0.55	-3.18%	10.72%	2.17%	10/29/2026 (Estimated)

Latest CYRX, FTRE, ALMR, and BLFS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	BLFS BioLife Solutions	$0.05	N/A	N/A	N/A	$29.13 million	N/A
11/3/2026	Q3 2026	CYRX CryoPort	-$0.19	N/A	N/A	N/A	$48.69 million	N/A
10/29/2026	Q3 2026	FTRE Fortrea	$0.2172	N/A	N/A	N/A	$671.57 million	N/A
8/11/2026	Q2 2026	ALMR Alamar Biosciences	-$0.36	-$0.22	+$0.14	-$0.22	N/A	$29.43 million
8/6/2026	Q2 2026	BLFS BioLife Solutions	$0.0313	$0.91	+$0.8788	$0.91	$27.80 million	$28.47 million
8/6/2026	Q2 2026	CYRX CryoPort	-$0.1933	-$0.20	-$0.0067	-$0.20	$48.18 million	$48.97 million
7/29/2026	Q2 2026	FTRE Fortrea	$0.1804	$0.23	+$0.0496	-$0.14	$647.57 million	$678.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALMR Alamar Biosciences	N/A	N/A	N/A	N/A	N/A
BLFS BioLife Solutions	N/A	N/A	N/A	N/A	N/A
CYRX CryoPort	N/A	N/A	N/A	N/A	N/A
FTRE Fortrea	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALMR Alamar Biosciences	0.03	11.85	10.23
BLFS BioLife Solutions	N/A	9.69	7.14
CYRX CryoPort	N/A	2.08	1.98
FTRE Fortrea	1.98	0.96	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALMR Alamar Biosciences	N/A
BLFS BioLife Solutions	93.24%
CYRX CryoPort	92.90%
FTRE Fortrea	N/A

Insider Ownership

Company	Insider Ownership
ALMR Alamar Biosciences	N/A
BLFS BioLife Solutions	2.20%
CYRX CryoPort	9.50%
FTRE Fortrea	0.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALMR Alamar Biosciences	222	69.39 million	N/A	N/A
BLFS BioLife Solutions	440	48.92 million	47.85 million	Optionable
CYRX CryoPort	738	50.65 million	45.84 million	Optionable
FTRE Fortrea	14,300	95.10 million	94.41 million	Optionable

CYRX, FTRE, ALMR, and BLFS Headlines

Recent News About These Companies

Fortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?

4 hours ago | zacks.com

Fortrea (FTRE) Projected to Announce Quarterly Earnings on Thursday

October 22 at 5:10 AM | marketbeat.com

Fortrea (NASDAQ:FTRE) Stock Gets Price Target Increase from UBS Group

October 22 at 2:13 AM | americanbankingnews.com

Fortrea (NASDAQ:FTRE) Reaches New 12-Month High Following Analyst Upgrade

October 22 at 1:21 AM | americanbankingnews.com

Fortrea : Why global sponsors are increasingly including China early in multi-regional clinical trials

October 21 at 1:45 PM | marketscreener.comM

Fortrea (NASDAQ:FTRE) Hits New 52-Week High After Analyst Upgrade

October 20 at 2:19 PM | marketbeat.com

UBS Group Issues Positive Forecast for Fortrea (NASDAQ:FTRE) Stock Price

October 20 at 9:05 AM | marketbeat.com

Fortrea Completes $45 Mln Acquisition Of Worldwide's Early Phase Services Divisions

October 20 at 8:20 AM | rttnews.com

Fortrea Holdings Inc: Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials

October 19 at 7:35 PM | finanznachrichten.de

Fortrea buys Worldwide Clinical Trials early phase unit for $45M

October 19 at 7:35 PM | streetinsider.com

Is Fortrea Holdings (FTRE) Still Cheap After Its 116% Run?

October 19 at 7:35 PM | finance.yahoo.com

Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials

October 19 at 4:05 PM | globenewswire.com

Deutsche Bank Upgrades Fortrea to Buy From Hold, $25 Price Target

October 15, 2026 | finance.yahoo.com

Fortrea (NASDAQ:FTRE) Stock Rating Lowered by Zacks Research

October 14, 2026 | marketbeat.com

Fortrea : How China's regulatory evolution is accelerating rare disease drug development

October 13, 2026 | marketscreener.comM

Fortrea (NASDAQ:FTRE) Upgraded at Wall Street Zen

October 10, 2026 | marketbeat.com

Ausbil Investment Management Ltd Decreases Stake in Fortrea Holdings Inc. $FTRE

October 8, 2026 | marketbeat.com

Barclays Upgrades Fortrea Holdings to Overweight From Equalweight

October 6, 2026 | marketscreener.comM

Fortrea (NASDAQ:FTRE) Reaches New 52-Week High - What's Next?

October 6, 2026 | marketbeat.com

Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call

October 5, 2026 | globenewswire.com

Fortrea (NASDAQ:FTRE) Stock Rating Upgraded by UBS Group

October 1, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX, FTRE, ALMR, and BLFS Company Descriptions

Alamar Biosciences NASDAQ:ALMR

$29.58 -1.87 (-5.95%)

As of 02:57 PM Eastern

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, enabling researchers to establish the relationship between incremental changes in multiplexed protein biomarkers and the clinically meaningful differences in health, disease and drug therapy. Our integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. We commercially launched our proprietary instrument, the ARGO High Throughput (“HT”) System in January 2024 and have already experienced rapid adoption, with more than 300 customers across 25 countries and a cumulative installed base of over 100 instruments with an average annual pull-through greater than $400,000 per instrument for the year ended December 31, 2025. The robust performance of our platform is further evidenced in over 100 scientific publications since our commercial launch. Our customers include top global research and academic institutions, biopharmaceutical companies, contract research organizations and service labs. All ten of the top ten biopharma companies by 2024 revenue are customers of Alamar. We are also developing a second proprietary instrument as part of our IVD platform, called the ARGO HT/DX instrument, for which we intend to provide a submission to the FDA for marketing authorization in 2027. We have established multiple multi-million dollar collaborations with renowned research foundations to help support the development of our ARGO HT/DX instrument and the discovery of biomarkers in neurodegenerative disease. Proteins are essential for all life functions and the fundamental molecules behind healthy cellular operations and the causal mechanisms of disease, as illustrated by the fact that a large majority of effective drugs have proteins as targets. Proteomic analysis has great potential to identify “biomarkers” of health, to characterize disturbances in disease, to discover new drug targets, to assess risks and to measure the impact of interventions such as drugs and lifestyle changes. However, the complexity of disease and biology requires analysis of multiple proteins and pathways at once. As a result of this complexity, much of the human proteome has remained unmeasurable or unquantifiable by other proteomic technologies, and true Precision Proteomics has not been possible. Our proprietary and patented NULISA technology addresses these critical limitations, and we believe it is currently the only platform that enables Precision Proteomics. The chemistry underpinning our technology employs a unique sequential purification of immunocomplexes to suppress background noise and enable the detection of low-abundance protein targets in biofluids across large and diverse populations. Our platform is a fully integrated and fully automated proteomic analysis solution and provides scientists with an end-to-end solution to precisely and consistently measure from one to over one hundred low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research, and ultimately, diagnostics. Scientists value our platform because it offers an accessible, easy-to-use and reliable ultra-high sensitivity and multiplexed biomarker analysis of large cohorts of samples. Our current instrument, the ARGO HT System, is designed to fully automate high-sensitivity and high-plex proteomics analysis and is currently available for research use only (“RUO”) applications. It was built to execute our NULISA chemistry in a simple and reproducible workflow for broad biomarker profiling, validation and potential translation into future clinical use. The ARGO HT System facilitates the seamless analysis of large cohorts and clinical research with minimal handling, rapid turnaround times and high data quality. Our initial assay menu focuses on neurology and immunology. We develop a significant portion of our assay panels in close partnership with our customers, who are experts in identifying important protein biomarkers in their respective fields. Our flagship multiplex assay, the CNS Disease Panel 120, provides broad coverage of neurodegeneration pathways. Additionally, our single-plex BD-pTau217 assay can distinctly measure brain-derived-pTau217, which is present in low abundance in blood and is critical for research involving biomarkers for early diagnosis of Alzheimer’s disease. Our assay enables BD-pTau217 quantitation using a small blood sample, offering a noninvasive, economical and convenient alternative to cerebrospinal fluid sample tests or PET scans. We also develop kits for customers to create their own assays, enabling our technology to meet the needs of customers operating in their disease areas of interest. The flexibility of our platform is designed to enable researchers to seamlessly transition from high-plex discovery panels to the development of low-plex diagnostics assays. As a result, our strategy is to continue driving adoption in the targeted discovery and translational markets and subsequently establish a foundation for clinical diagnostics through internal innovation and external collaborations. Ultimately, our platform is designed to support the entire customer journey from discovery to diagnostics, unlocking the full value of precision medicine and early disease detection. We were founded in May 2018 as a Delaware corporation. Our principal executive offices are located in Fremont, California.

BioLife Solutions NASDAQ:BLFS

$38.61 0.00 (0.00%)

As of 10/21/2026

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

CryoPort NASDAQ:CYRX

$17.82 -0.71 (-3.83%)

As of 03:13 PM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Fortrea NASDAQ:FTRE

$23.73 -0.33 (-1.37%)

As of 03:14 PM Eastern

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CYRX, FTRE, ALMR, and BLFS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CYRX, FTRE, ALMR, and BLFS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CYRX, FTRE, ALMR, and BLFS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX, FTRE, ALMR, and BLFS Company Descriptions

Alamar Biosciences NASDAQ:ALMR

BioLife Solutions NASDAQ:BLFS

CryoPort NASDAQ:CYRX

Fortrea NASDAQ:FTRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CYRX, FTRE, ALMR, and BLFS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CYRX, FTRE, ALMR, and BLFS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CYRX, FTRE, ALMR, and BLFS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX, FTRE, ALMR, and BLFS Company Descriptions

Alamar Biosciences NASDAQ:ALMR

BioLife Solutions NASDAQ:BLFS

CryoPort NASDAQ:CYRX

Fortrea NASDAQ:FTRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools